FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2472164676> ?p ?o ?g. }

• W2472164676 endingPage "82" @default.
• W2472164676 startingPage "473" @default.
• W2472164676 abstract "To study the role of postoperative chemotherapy and its prognostic effect in Masaoka-Koga stage III and IV thymic tumors.Between 1994 and 2012, 1,700 patients with thymic tumors who underwent surgery without neoajuvant therapy were enrolled for the study. Among them, 665 patients in Masaoka-Koga stage III and IV were further analyzed to evaluate the clinical value of postoperative chemotherapy. The Kaplan-Meier method was used to obtain the survival curve of the patients divided into different subgroups, and the Cox regression analysis was used to make multivariate analysis on the factors affecting prognosis. A Propensity-Matched Study was used to evaluate the clinical value of chemotherapy.Two-hundred-twenty-one patients were treated with postoperative chemotherapy, while the rest 444 cases were not. The two groups showed significant differences (P<0.05) regarding the incidence of myasthenia gravis, World Health Organization (WHO) histological subtypes, pathological staging, resection status and the use of postoperative radiotherapy. WHO type C tumors, incomplete resection, and postoperative radiotherapy were significantly related to increased recurrence and worse survival (P<0.05). Five-year and 10-year disease free survivals (DFS) and recurrence rates in patients who underwent surgery followed by postoperative chemotherapy were 51% and 30%, 46% and 68%, comparing with 73% and 58%, 26% and 40% in patients who had no adjuvant chemotherapy after surgery (P=0.001, P=0.001, respectively). In propensity-matched study, 158 pairs of patients with or without postoperative chemotherapy (316 patients in total) were selected and compared accordingly. Similar 5-year survival rates were detected between the two groups (P=0.332).Pathologically higher grade histology, incomplete resection, and postoperative radiotherapy were found to be associated with worse outcomes in advanced stage thymic tumors. At present, there is no evidence to show that postoperative chemotherapy may help improve prognosis in patients with Masaoka-Koga-Koga stage III and IV thymic tumors.背景与目的 探讨术后化疗在胸腺肿瘤中的应用及术后化疗对Masaoka III期/IV期预后的影响。方法 1994年3月至2012年12月，中国胸腺瘤研究协作组（Chinese Alliance of Research for Thymomas, ChART）数据库共纳入2,306例胸腺肿瘤病例，资料相对完整1,700例患者纳入本研究，对其中Masaoka III期/IV期665例患者进行进一步分析，初步评估术后化疗的临床价值，采用Kaplan-Meier法绘制不同亚组患者生存曲线，Cox回归进行多因素分析影响预后的因素。采用倾向值匹配研究（propensity-matched study, PSM），评估化疗的临床价值。结果 1,700例患者中未行术后化疗1,406例（82.7%），术后化疗294例（17.3%），随着Masaoka分期的增加，术后化疗患者的比例也随之增高，差异有统计学意义（P<0.001）。对Masaoka III期/IV期患者665例进行进一步分析，其中未术后化疗组444例，术后化疗组221例。两组患者在有无重症肌无力、WHO病理类型、病理分期、手术根治性、有无术后放疗等方面分布有差异（P<0.05）。其中C型胸腺瘤、不完全切除和术后放疗明显影响患者术后复发和生存（P<0.05）。术后化疗组5年和10年无病生存率分别为51%、30%，5年和10年复发率分别为46%、68%，而未术后化疗组5年和10年无病生存率分别为73%、58%。5年和10年复发率分别为26%、40%，两组无病生存率和复发率均有明显统计学差异（P=0.001, P=0.001）。对有无重症肌无力，病理类型，病理分期，手术根治性状态，术后放疗等因素进行倾向值匹配筛选出其中158例未术后化疗和158例术后化疗共316例患者，生存分析显示：未术后化疗组和术后化疗组两组5年生存率并无明显统计学差异（P=0.332）。结论 病理学类型、手术的根治性和术后放疗是影响进展期胸腺肿瘤患者术后生存和复发的主要因素。术后化疗并未给Masaoka-Koga III期/IV期胸腺瘤患者带来生存获益。." @default.
• W2472164676 created "2016-07-22" @default.
• W2472164676 creator A5010320756 @default.
• W2472164676 creator A5011303359 @default.
• W2472164676 creator A5011910181 @default.
• W2472164676 creator A5022164362 @default.
• W2472164676 creator A5026364190 @default.
• W2472164676 creator A5032710067 @default.
• W2472164676 creator A5034168706 @default.
• W2472164676 creator A5042806821 @default.
• W2472164676 creator A5044652383 @default.
• W2472164676 creator A5046214153 @default.
• W2472164676 creator A5048765297 @default.
• W2472164676 creator A5050540557 @default.
• W2472164676 creator A5053573702 @default.
• W2472164676 creator A5056684346 @default.
• W2472164676 creator A5059294101 @default.
• W2472164676 creator A5060592435 @default.
• W2472164676 creator A5066941603 @default.
• W2472164676 creator A5068979363 @default.
• W2472164676 creator A5069038578 @default.
• W2472164676 creator A5070617771 @default.
• W2472164676 creator A5079564946 @default.
• W2472164676 creator A5083790930 @default.
• W2472164676 date "2016-07-20" @default.
• W2472164676 modified "2023-09-25" @default.
• W2472164676 title "[Application of Postoperative Chemotherapy on Thymomas and Its Prognostic Effect]." @default.
• W2472164676 cites W1894601853 @default.
• W2472164676 cites W1983886870 @default.
• W2472164676 cites W2012510274 @default.
• W2472164676 cites W2022760113 @default.
• W2472164676 cites W2025264147 @default.
• W2472164676 cites W2037342610 @default.
• W2472164676 cites W2053244130 @default.
• W2472164676 cites W2067540788 @default.
• W2472164676 cites W2083719902 @default.
• W2472164676 cites W2091342567 @default.
• W2472164676 cites W2110654155 @default.
• W2472164676 cites W2134232546 @default.
• W2472164676 cites W2141720524 @default.
• W2472164676 cites W2297391501 @default.
• W2472164676 doi "https://doi.org/10.3779/j.issn.1009-3419.2016.07.10" @default.
• W2472164676 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6133974" @default.
• W2472164676 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27339725" @default.
• W2472164676 hasPublicationYear "2016" @default.
• W2472164676 type Work @default.
• W2472164676 sameAs 2472164676 @default.
• W2472164676 citedByCount "0" @default.
• W2472164676 crossrefType "journal-article" @default.
• W2472164676 hasAuthorship W2472164676A5010320756 @default.
• W2472164676 hasAuthorship W2472164676A5011303359 @default.
• W2472164676 hasAuthorship W2472164676A5011910181 @default.
• W2472164676 hasAuthorship W2472164676A5022164362 @default.
• W2472164676 hasAuthorship W2472164676A5026364190 @default.
• W2472164676 hasAuthorship W2472164676A5032710067 @default.
• W2472164676 hasAuthorship W2472164676A5034168706 @default.
• W2472164676 hasAuthorship W2472164676A5042806821 @default.
• W2472164676 hasAuthorship W2472164676A5044652383 @default.
• W2472164676 hasAuthorship W2472164676A5046214153 @default.
• W2472164676 hasAuthorship W2472164676A5048765297 @default.
• W2472164676 hasAuthorship W2472164676A5050540557 @default.
• W2472164676 hasAuthorship W2472164676A5053573702 @default.
• W2472164676 hasAuthorship W2472164676A5056684346 @default.
• W2472164676 hasAuthorship W2472164676A5059294101 @default.
• W2472164676 hasAuthorship W2472164676A5060592435 @default.
• W2472164676 hasAuthorship W2472164676A5066941603 @default.
• W2472164676 hasAuthorship W2472164676A5068979363 @default.
• W2472164676 hasAuthorship W2472164676A5069038578 @default.
• W2472164676 hasAuthorship W2472164676A5070617771 @default.
• W2472164676 hasAuthorship W2472164676A5079564946 @default.
• W2472164676 hasAuthorship W2472164676A5083790930 @default.
• W2472164676 hasConcept C120665830 @default.
• W2472164676 hasConcept C121332964 @default.
• W2472164676 hasConcept C126322002 @default.
• W2472164676 hasConcept C141071460 @default.
• W2472164676 hasConcept C143998085 @default.
• W2472164676 hasConcept C146357865 @default.
• W2472164676 hasConcept C151730666 @default.
• W2472164676 hasConcept C17923572 @default.
• W2472164676 hasConcept C207886595 @default.
• W2472164676 hasConcept C2776256026 @default.
• W2472164676 hasConcept C2776694085 @default.
• W2472164676 hasConcept C38180746 @default.
• W2472164676 hasConcept C50382708 @default.
• W2472164676 hasConcept C509974204 @default.
• W2472164676 hasConcept C61511704 @default.
• W2472164676 hasConcept C71924100 @default.
• W2472164676 hasConcept C86803240 @default.
• W2472164676 hasConceptScore W2472164676C120665830 @default.
• W2472164676 hasConceptScore W2472164676C121332964 @default.
• W2472164676 hasConceptScore W2472164676C126322002 @default.
• W2472164676 hasConceptScore W2472164676C141071460 @default.
• W2472164676 hasConceptScore W2472164676C143998085 @default.
• W2472164676 hasConceptScore W2472164676C146357865 @default.
• W2472164676 hasConceptScore W2472164676C151730666 @default.
• W2472164676 hasConceptScore W2472164676C17923572 @default.
• W2472164676 hasConceptScore W2472164676C207886595 @default.
• W2472164676 hasConceptScore W2472164676C2776256026 @default.

• next